biostudies-literatureUnknown14Balagurunathan Y<h4>Background</h4>Relapsed and refractory Diffuse large B cell lymphoma (DLBCL) can be successfully treated with axicabtagene ciloleucel (axi-cel), a CD19-directed autologous chimeric antigen receptor T cell (CAR-T) therapy. Diagnostic image-based features could help identify the patients who would clinically respond to this advanced immunotherapy.<h4>Purpose</h4>The aim of this study was to establish a radiomic image feature-based signature derived from positron emission tomography/computed tomography (PET/CT), including metabolic tumor burden, which can predict a durable response to CAR-T therapy in refractory/relapsed DLBCL.<h4>Methods</h4>We conducted a retrospective review of 155 patients with relapsed/refractory DLBCL treated with axi-cel CAR-T therapy. The patients' disease involveFrontiers in oncology1485039https://www.ebi.ac.uk/biostudies/studies/S-EPMC11629080biostudies-literatureRadiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy.PMC11629080Mattie MLocke FLQi JKim JJJain MChoi JWWei ZBalagurunathan YDean ELu HThompson ZVardhanabhuti SCorallo SfalseRadiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy.<h4>Background</h4>Relapsed and refractory Diffuse large B cell lymphoma (DLBCL) can be successfully treated with axicabtagene ciloleucel (axi-cel), a CD19-directed autologous chimeric antigen receptor T cell (CAR-T) therapy. Diagnostic image-based features could help identify the patients who would clinically respond to this advanced immunotherapy.<h4>Purpose</h4>The aim of this study was to establish a radiomic image feature-based signature derived from positron emission tomography/computed tomography (PET/CT), including metabolic tumor burden, which can predict a durable response to CAR-T therapy in refractory/relapsed DLBCL.<h4>Methods</h4>We conducted a retrospective review of 155 patients with relapsed/refractory DLBCL treated with axi-cel CAR-T therapy. The patients' disease involve2024-01-01T00:00:00Z20242025-04-26T23:16:11.997Z2025-04-06T17:32:05.146ZS-EPMC116290803965977910.3389/fonc.2024.1485039